Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2017.5660

OL-0-0-5660

Articles

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

Nandie

1 * Huang

Ying

1 * Zou

Zhengyun

1 Gimenez-Capitan

Ana

2 Yu

Lixia

1 Hu

Wenjing

1 Zhu

Lijing

1 Sun

Xia

1 Sanchez

Jose Javier

3 Guan

Wenxian

4 Liu

Baorui

1 Rosell

Rafael

2 5 Wei

Jia

1The Comprehensive Cancer Centre of Drum Tower Hospital, Department of Oncology, The Affiliated Drum Tower Hospital of Nanjing University, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu 210008, P.R. China 2Pangaea Biotech, Department of Oncology, USP Dexeus University Institute, Barcelona 08001, Spain 3Department of Preventive Medicine and Public Health, Autonomous University of Madrid, Madrid 28001, Spain 4Department of General Surgery, The Affiliated Drum Tower Hospital of Nanjing University, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China 5Department of Medical Oncology, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona 08916, Spain

Correspondence to: Professor Jia Wei, The Comprehensive Cancer Centre of Drum Tower Hospital, Department of Oncology, The Affiliated Drum Tower Hospital of Nanjing University, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, 321 Zhongshan Road, Nanjing, Jiangsu 210008, P.R. China, E-mail: weijia01627@hotmail.com *

Contributed equally

03 2017

01 02 2017

13 3 1826 1834 31032015 22042016

2017

Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS). All 131 patients received first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, in which 56 patients were further treated with second-line docetaxel-based chemotherapy. A correlation between the mRNA expression levels of BIM and AEG-1 was observed (r_s=0.30; P=0.002). There was no association between the mRNA expression levels of any of the individual genes analyzed and OS in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM exhibited a median OS of 18.2 months [95% confidence interval (CI), 12.8–23.6], compared with 9.6 months (95% CI, 8.9–10.3) in patients with low BIM levels (P=0.008). However, there was no correlation between the mRNA expression levels of AEG-1 or AXL and OS. The risk of mortality was higher in patients with low BIM mRNA levels than in those with high or intermediate BIM mRNA levels (hazard ratio, 2.61; 95% CI, 1.21–5.62; P=0.010). Therefore, BIM may be considered as a biomarker to identify whether patients could benefit from docetaxel-based second-line chemotherapy in GC.

gene expression BIM second-line docetaxel-based chemotherapy gastric cancer apoptosis

Introduction

The incidence of gastric cancer (GC) ranks as the fifth most frequent among all types of cancer worldwide (1). Nearly 40% of all GC cases occur in China, and are often diagnosed in advanced stages (2). The median overall survival (OS) for GC patients remains <12 months with first-line oxaliplatin, 5-fluorouracil (5-FU) and folinic acid treatment (3). Of all GC patients, ~1/2 could be candidates for second-line treatment at the time of failure of first-line chemotherapy (4). Docetaxel is among the most frequently used agents for GC second-line treatment (5). In a previous study by the present authors, the median OS was 25.8 months for patients with high messenger RNA (mRNA) expression levels of breast cancer susceptibility gene 1 (BRCA1) treated with second-line docetaxel-based chemotherapy (6). Recent evidence also suggests that an underlying cause of drug resistance may be the failure of drug-induced apoptosis (7–9). Platinum treatment initiates apoptosis through the formation of DNA adducts, which primarily form intrastrand crosslinks that activate the apoptotic pathway, eventually resulting in cell death (10,11). The most recognized mechanism of docetaxel-based regimen is the binding to microtubules, which arrests the cell cycle in G2/M and eventually leads to cell death (12).

B-cell lymphoma 2 (BCL-2) interacting mediator of cell death (BIM) belongs to the BCL-2 protein family, and is also a member of the BCL-2-homology 3-only (BH3-only) family (13). BIM is expressed in a wide variety of tissues, including GC, and acts as a pivotal regulator of the mitochondrial apoptosis pathway (14). Abnormal levels of BIM have been recognized to affect the chemotherapy response (15). Platinum-resistant cancer cells conserved sensitivity to BH3-induced mitochondrial apoptosis (16). In line with that, BH3-mimetic compounds such as ABT-737 were able to sensitize cancer cells to platinum (17). In addition, overexpression of BIM enhanced the in vitro sensitivity to docetaxel of non-small cell lung cancer (NSCLC) (18). Consistent with this finding, downregulation of BIM by small interfering RNA (siRNA) delayed paclitaxel-mediated apoptosis, indicating that low BIM expression levels were responsible for resistance to paclitaxel (19). Notably, pre-treatment mRNA levels of BIM strongly predicted the capacity of epidermal growth factor receptor (EGFR), human EGFR 2 (HER2) and phosphoinositide 3-kinase (PI3K) inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha-mutant tumors, respectively (20). In a previous study, the present authors observed that patients with high BIM expression achieved longer survival in EGFR-mutant NSCLC treated with erlotinib or chemotherapy (21).

Astrocyte elevated gene-1 (AEG-1) was originally identified as a novel gene induced by human fetal astrocytes following infection with human immunodeficiency virus 1 (22). AEG-1 does not impact the uptake or retention of chemotherapy drugs; instead, AEG-1 increases chemoresistance by enhancing cell survival (23). Overexpression of AEG-1 suppresses apoptosis through phosphorylation of substrates of the anti-apoptotic protein kinase B (also known as AKT) (24), and is important in promoting cancer malignant behavior (25). In previous studies, AEG-1 overexpression correlated with poor prognosis in GC (25) and NSCLC (26). It has been confirmed that AEG-1 contributed to resistance to chemotherapeutic drugs such as 5-FU in hepatocellular carcinoma cell lines (27). Furthermore, knockdown of AEG-1 sensitized breast cancer cell lines to paclitaxel in vitro and in vivo (23). Low AEG-1 expression was associated with longer progression-free survival in platinum-based chemotherapy in NSCLC (28). In addition, AEG-1 mRNA expression correlated with BRCA1 expression (28), which induced sensitivity to docetaxel (6).

AXL receptor tyrosine kinase (AXL) belongs to the Tyro3, AXL and Mer family (29). Growth arrest-specific gene 6 (Gas6) is the ligand of AXL (30). In conjunction with each other, Gas6/AXL signaling may enhance cell survival (31). Activation of Gas6/AXL signaling induced the activation of the PI3K signaling pathway, which increased the expression of anti-apoptotic proteins such as BCL-2 and BCL-extra large (BCL-XL) (32). Overexpression of AXL was responsible for tumor growth in mesothelioma (33), lung cancer (34) and breast cancer (35). Furthermore, increased AXL activation has been linked with cisplatin resistance in ovarian cancer (36).

In the present study, the mRNA expression levels of BIM, AEG-1 and AXL were examined in 131 advanced GC samples. In addition, the expression levels of the above genes were correlated with patients' clinicopathological features and OS to first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, with or without second-line docetaxel-based chemotherapy.

Patients and methods <sec> <title>Study population

A total of 131 advanced GC samples in which BRCA1 mRNA expression levels had been previously determined (6) were included in the present study. Patients' clinical characteristics are indicated in Table I. All patients received a combination of oxaliplatin, 5-fluorouracil (FU) and folinic acid (FOLFOX) as first-line therapy (85 mg/m² oxaliplatin plus 200 mg/m² folinic acid and 600 mg/m² 5-FU every for 2 weeks until disease progression) for a median of 3 cycles (range, 1–8 cycles). A total of 34 patients received single-agent docetaxel (35 mg/m²), and the remaining 22 patients were treated with docetaxel-based doublets (6 patients received 35 mg/m² docetaxel plus 100 mg/m² irinotecan weekly for 3 weeks, every 4 weeks until disease progression; 11 patients received 35 mg/m² docetaxel weekly for 3 weeks plus 1,000 mg/m² capecitabine daily for 2 weeks, every 4 weeks until disease progression; and 5 patients received 35 mg/m² docetaxel weekly for 3 weeks plus 6 mg/m² hydroxycamptothecin on days 1 and 5, every 4 weeks until disease progression) for a median of 3 cycles (range, 1–7 cycles). Following progression, 56 patients further received docetaxel-based second-line chemotherapy. A total of 34 patients received single-agent docetaxel, and the remaining 22 patients were treated with docetaxel-based doublets, based on their response to first-line chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) and patient consent. Survival was calculated from the starting date of first-line treatment to the date of last follow-up or mortality from any cause. Approval was obtained from the patients and from the ethics committee of Drum Tower Hospital (Nanjing, China).

Gene expression analysis

Gene expression profiling was performed on RNA isolated from macrodissected tumor tissues containing ≥80% of tumor cells, in accordance with a proprietary procedure (European patent publication no. EP1945764-B1). Primers and probes for gene expression analysis of BIM, AEG-1 and AXL are indicated in Table II. The mRNA levels of BIM, AEG-1 and AXL were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) using Taqman^® Universal PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the comparative Cq method (37). β-actin was used as an endogenous control, and commercial RNA controls (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA) were used as calibrators. RT-qPCR was conducted in a 7900HT Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The reactions were initiated by heating to 50°C for 2 min and then to 95°C for 2 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec.

Statistical analysis

Gene expression levels were analyzed as categorical variables by terciles. Correlations between gene expression and clinicopathological parameters were analyzed with the χ² test. Correlations among different genes were conducted using Spearman's correlation coefficient analysis. Stratified log-rank tests were used to assess the median OS. Estimation of survival curves was performed with the Kaplan-Meier method. A multivariate analysis was performed using the Cox proportional hazards regression model. All analyses were performed with SPSS version 17.0 software (SPSS, Inc.,Chicago, IL, USA). Two-sided P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Distribution and clinicopathological features of all patients

A total of 131 advanced GC samples were included in the study, of which, 100 were males and 31 females. The median age of all patients enrolled was 59.6 years (range, 22–84 years). All patients were pathologically confirmed as adenocarcinoma, of which, 79 patients (60.3%) were confirmed with stage III and 52 patients (39.7%) with stage IV disease (Table I).

Correlations among different genes

A correlation was observed between BIM and AEG-1 mRNA expression (r_s=0.30; P=0.002). However, no associations were observed between BIM, AXL and AEG-1 mRNA expression (P=0.100 and 0.140 respectively).

Association between OS and clinicopathological characteristics

The median OS was 11.6 months (95% CI, 9.8–13.6) in all patients. Among the patients with stage III disease, the median OS was 12.9 months, compared with 9.6 months among the patients with stage IV disease (P=0.001). Notably, the median OS was ~12.5 months for patients with ECOG PS=0–1 vs. 6.3 months for patients with ECOG PS=2 (P<0.001). There was no significant association between OS and age (P=0.300), gender (P=0.630), tumor site (P=0.110) or histological grade (P=0.070) (Table III).

Survival for GC patients according to mRNA expression levels

No association was observed between OS and the mRNA expression levels of BIM (P=0.170), AEG-1 (P=0.360) and AXL (P=0.250) in all 131 patients, respectively (Figs. 1–3).

Among the 75 patients receiving only first-line FOLFOX chemotherapy, a trend towards longer survival was observed in those with low BIM levels (P=0.080). However, there was no difference in survival according to their AEG-1 (P=0.810) or AXL mRNA expression levels (P=0.350).

Among the 56 patients receiving additional docetaxel-based second-line chemotherapy, the median OS was 9.6 months (95% CI, 8.9–10.3) for patients with low levels of BIM, 25.2 months (95% CI, 12.5–37.9) for those with intermediate BIM levels and 15.7 months (95% CI, 9.4–22.0) for those with high BIM levels (P=0.021). Considering the obvious trend of a longer OS in patients with higher BIM expression, high and intermediate expression groups were merged into a whole group for further analysis (Fig. 4). Patients with high or intermediate levels of BIM exhibited a median OS of 18.2 months (95% CI, 12.8–23.6), while patients with low BIM exhibited a median OS of just 9.6 months (95% CI, 8.9–10.3; P=0.008). Longer survival was also observed in patients with high levels of AEG-1 (P=0.080), although the difference was not significant. There was no difference in OS according to the expression levels of AXL (P=0.600).

To further understand the role of BIM as a predictive biomarker, multivariate analysis of OS was performed. Patients with low BIM mRNA levels had higher mortality than those with high or intermediate BIM mRNA levels (HR of mortality, 2.61; 95% CI, 1.21–5.62; P=0.010). Lower risk of mortality was observed in patients with ECOG PS=0–1 compared with those with ECOG PS=2 (HR, 0.17; 95% CI, 0.04–0.65; P=0.010) in patients with stage III tumors, compared with patients with stage IV tumors (HR, 0.37; 95% CI, 0.17–0.82; P=0.010) (Table IV).

Discussion

Following the failure of first-line chemotherapy, several drugs are recommended for second-line regimens, including paclitaxel, docetaxel and irinotecan (38). The median OS of patients receiving second-line docetaxel-based regimens ranges from 3.5 to 10.9 months, which is still dismal (5). The present authors previously observed that GC patients with high BRCA1 levels could benefit from receiving second-line docetaxel-based chemotherapy (6). In addition, the median OS was further prolonged for patients with high levels of BRCA1 and multiple myeloma SET domain (39).

The DNA damage caused by chemotherapy leads to cell cycle arrest, DNA repair or commitment to apoptosis (40). Failure of drug-induced apoptosis is a vital reason for chemoresistance (41). A previous study identified that overexpression of genes involved in apoptosis appeared to contribute to docetaxel sensitivity in breast cancer through high-throughput screening of thousands of genes (42). It is commonly known that taxanes interfere with the dynamics of the microtubules and induce apoptosis through the mitochondrial apoptotic pathway (43).

In the present study, a marked difference in OS (18.2 vs. 9.6 months) was observed in patients receiving second-line docetaxel-based chemotherapy, according to their BIM mRNA expression levels in univariate analysis (P=0.008). In addition, this association was also significant in multivariate analysis, which further confirmed the role of BIM as a predictive biomarker. Patients with low BIM mRNA levels exhibited higher mortality than those with high or intermediate BIM mRNA levels (HR, 2.61; 95% CI, 1.21–5.62; P=0.010). These results were consistent with previously published data suggesting that overexpression of BIM was accompanied by a collateral increase in sensitivity to taxanes (19), which may translate into prolonged OS.

BIM is an important mediator of tumor cell death (15). Other studies have previously demonstrated that several kinase-driven tumors, including chronic myelogenous leukemia and NSCLC, maintain a survival advantage by suppressing BIM transcription and by targeting BIM protein for proteasomal degradation (44–46). Numerous studies have clearly demonstrated that activation of the PI3K/AKT signaling pathway could regulate BIM expression (44,47). The PI3K/AKT signaling pathway triggers a cascade of cell responses, including cell cycle progression, programmed cell death and DNA damage repair in cancer (48). Furthermore, the PI3K/AKT signaling pathway is closely associated with the development and recurrence of cancer (49). The class O of forkhead box (FOXO) transcription factors are downstream effectors of the PI3K/AKT signaling pathway (50). When active, FOXOs induce cell cycle arrest and apoptosis, acting as anti-proliferative factors (51). BIM is mainly regulated by FOXO3a, a member of the FOXO family (52). Following an apoptotic-stress event, BIM translocates to the mitochondria, and is essential to mediate the release of cytochrome c from the mitochondria, which in turn activates the effector caspase-9 and the formation of the apoptosome (53). Previous studies reported that the PI3K inhibitor LY294002 could increase BIM expression and cell death, which partly demonstrated a modulating role of PI3K/AKT signaling on BIM expression (47). The aforementioned results are in agreement with the pattern of FOXO3a dephosphorylation and nuclear translocation. The dephosphorylation status of AKT inhibits the nuclear export of its substrate FOXO3a to the cytoplasm, which transactivates the main target gene, BIM, to cause cell cycle arrest and cell death (52). In a previous study, BIM mRNA levels could be increased by upregulation of FOXO3a following paclitaxel treatment, leading to apoptosis in breast cancer cells and contributing to tumor sensitivity to paclitaxel (54). Thus, the impact of BIM and other BH3-only proteins in GC patients through apoptosis pathways should be further investigated.

AEG-1 was identified as an oncogene that caused detrimental effects to patients' OS through preventing cancer cells from undergoing apoptosis (55). Overexpression of AEG-1 leads to the activation of the PI3K/AKT pro-survival signaling pathway and the downregulation of BCL-2 associated agonist of cell death (BAD), p21, p27 and FOXO3a (24). In addition, increasing expression and activation of FOXO3a by AEG-1 knockdown further confirms this mechanism (56). AXL, a receptor tyrosine kinase, was originally cloned from cancer cells (57). A crucial step in AXL-dependent signal transduction is the activation of PI3K/AKT (58). The activation of AXL protects cells from apoptosis and increases the expression of the anti-apoptotic proteins BCL-2 and BCL-XL (59), as well as the phosphorylation of BAD (60). AXL is also implicated in angiogenesis (61) and immune response (62). Preclinical findings and retrospective studies have illustrated that overexpression of AEG-1 and AXL confers broad drug resistance to chemotherapeutic agents, including paclitaxel (63), cisplatin (64,65) and 5-FU (27). However, no correlations were observed in the present study between AEG-1 and AXL mRNA expression levels and patients' outcome to chemotherapy, either in first-line or second-line chemotherapy. This reflects the complexity of tumor drug response and the fact that single genes may not be sufficient to predict the therapeutic effect.

The present study has certain limitations. First, the number of patients included in the study is relatively small, which may cause bias in data analysis. In addition, the study is retrospective in nature. Furthermore, multiple gene models or signatures may be more effective than single biomarkers, as gene expression patterns associated with drug resistance and sensitivity are complex.

In conclusion, based on the significantly prolonged OS among patients with high or intermediate BIM mRNA expression in the present study, BIM may act as a potential biomarker in second-line docetaxel-based chemotherapy for GC. The findings in the current study pave the way for personalized chemotherapy in GC.

Acknowledgements

The present study was funded by grants from the National Natural Science Foundation of China (Beijing, China; grant no. 81000980, 81220108023 and 81370064), the Fundamental Research Funds for the Central Universities (Beijing, China; grant no. 20620140729), the Jiangsu Provincial Program of Medical Science (Nanjing, China; grant no. BL2012001) and the Distinguished Young Investigator Project of Nanjing (Nanjing, China; grant no. JQX12002).

References 1

Fock

Review article: The epidemiology and prevention of gastric cancer

Aliment Pharmacol Ther402502602014

10.1111/apt.12814

24912650

Wadhwa

Song

Lee

Yao

Wei

Ajani

Gastric cancer-molecular and clinical dimensions

Nat Rev Clin Oncol106436552013

10.1038/nrclinonc.2013.170

24061039

Wagner

Grothe

Haerting

Kleber

Grothey

Fleig

Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data

J Clin Oncol24290329092006

10.1200/JCO.2005.05.0245

16782930

Lim

Kim

Jun

Kim

Chang

Park

Uhm

Lee

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

BMC Cancer91102009

10.1186/1471-2407-9-110

19358705

Wesolowski

Lee

Kim

Is there a role for second-line chemotherapy in advanced gastric cancer?

Lancet Oncol109039122009

10.1016/S1470-2045(09)70136-6

19717092

Wei

Costa

Ding

Zou

Sanchez

Qian

Chen

Gimenez-Capitan

Meng

mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer

J Natl Cancer Inst103155215562011

10.1093/jnci/djr326

21862729

Yang

Fraser

Moll

Basak

Tsang

Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway

Cancer Res66312631362006

10.1158/0008-5472.CAN-05-0425

16540663

Yuan

Wang

Zhao

Qiu

Nie

Wei

BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and-resistant ovarian cancer cells

PLoS One6e205862011

10.1371/journal.pone.0020586

21655183

Asselin

Mills

Tsang

XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells

Cancer Res61186218682001

11280739

Jamieson

Lippard

Structure, recognition, and processing of cisplatin-DNA adducts

Chem Rev99246724981999

10.1021/cr980421n

11749487

Kelland

The resurgence of platinum-based cancer chemotherapy

Nat Rev Cancer75735842007

10.1038/nrc2167

17625587

Alberti

Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma

Eur Rev Med Pharmacol Sci17165816642013

23832735

Zheng

Follis

A Viacava

Kriwacki

Moldoveanu

Discoveries and controversies in BCL-2 protein-mediated apoptosis

FEBS J283269027002016

10.1111/febs.13527

26411300

Correia

Lee

Meng

Vincelette

Knorr

Ding

Nowakowski

Dai

Kaufmann

Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment

Biochim Biophys Acta1853165816712015

10.1016/j.bbamcr.2015.03.012

25827952

Iurlaro

Muñoz-Pinedo

Cell death induced by endoplasmic reticulum stress

FEBS J283264026522016

10.1111/febs.13598

26587781

Crawford

Chacko

Savage

McCoy

Redmond

Longley

Fennell

Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis

Apoptosis163113202011

10.1007/s10495-010-0561-1

21107700

Simonin

N'Diaye

Lheureux

Loussouarn

Dutoit

Briand

Giffard

Brotin

Blanc-Fournier

Poulain

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis

Apoptosis184925082013

10.1007/s10495-012-0799-x

23344663

Inoue

Gika

Abiko

Oyama

Saitoh

Yamazaki

Nakamura

Abe

Kawamura

Kobayashi

Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer

Oncol Rep132592642005

15643508

Savry

Carre

Berges

Rovini

Pobel

Chacon

Braguer

Bourgarel-Rey

Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: Implications for cancer treatment

Neoplasia1549602013

10.1593/neo.121074

23358890

Faber

Corcoran

Ebi

Sequist

Waltman

Chung

Incio

Digumarthy

Pollack

Song

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Cancer Discov13523652011

10.1158/2159-8290.CD-11-0106

22145099

Costa

Molina

Drozdowskyj

Giménez-Capitán

Bertran-Alamillo

Karachaliou

Gervais

Massuti

Wei

Moran

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

Clin Cancer Res20200120102014

10.1158/1078-0432.CCR-13-2233

24493829

Kang

Chen

Pekarskaya

Chao

Volsky

Fisher

Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH

Oncogene21359236022002

10.1038/sj.onc.1205445

12032861

Wei

Kang

The multifaceted role of MTDH/AEG-1 in cancer progression

Clin Cancer Res15561556202009

10.1158/1078-0432.CCR-09-0049

19723648

Lee

Emdad

Sarkar

Franke

Fisher

Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling

Oncogene27111411212008

10.1038/sj.onc.1210713

17704808

Jian-bo

Hui

Yu-long

Chang-hua

Long-juan

Shi-rong

Wen-hua

Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer

Med Oncol284554622011

10.1007/s12032-010-9475-6

20300973

Song

Zhang

Liao

Dai

Ding

Zhang

Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer

J Pathol2193173262009

10.1002/path.2595

19644957

Yoo

Gredler

Vozhilla

Chen

Forcier

Shah

Saxena

Hansen

Fisher

Sarkar

Identification of genes conferring resistance to 5-fluorouracil

Proc Natl Acad Sci USA10612938129432009

10.1073/pnas.0901451106

19622726

Santarpia

Magri

Sanchez-Ronco

Costa

Molina-Vila

Gimenez-Capitan

Bertran-Alamillo

Mayo

Benlloch

Viteri

mRNA expression levels and genetic status of genes involved in the EGFR and NF-

B pathways in metastatic non-small-cell lung cancer patients

J Transl Med91632011

10.1186/1479-5876-9-163

21951562

Graham

DeRyckere

Davies

Earp

The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer

Nat Rev Cancer147697852014

10.1038/nrc3847

25568918

van der Meer

van der Poll

van 't Veer

TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis

Blood123246024692014

10.1182/blood-2013-09-528752

24596417

Papadakis

Cichoń

Vyas

Patel

Ghali

Cerio

Storey

O'Toole

Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members

J Invest Dermatol1315095172011

10.1038/jid.2010.326

21068757

Verma

Warner

Vankayalapati

Bearss

Sharma

Targeting Axl and Mer kinases in cancer

Mol Cancer Ther10176317732011

10.1158/1535-7163.MCT-11-0116

21933973

Corson

Flynn

Wise

Bueno

Sugarbaker

Fletcher

AXL regulates mesothelioma proliferation and invasiveness

Oncogene30164316522011

10.1038/onc.2010.555

21132014

Wimmel

Glitz

Kraus

Roeder

Schuermann

Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion

Eur J Cancer37226422742001

10.1016/S0959-8049(01)00271-4

11677117

Berclaz

Altermatt

Rohrbach

Kieffer

Dreher

Andres

Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast

Ann Oncol128198242001

10.1023/A:1011126330233

11484958

Macleod

Mullen

Sewell

Rabiasz

Lawrie

Miller

Smyth

Langdon

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

Cancer Res65678968002005

10.1158/0008-5472.CAN-04-2684

16061661

Bubner

Baldwin

Use of real-time PCR for determining copy number and zygosity in transgenic plants

Plant Cell Rep232632712004

10.1007/s00299-004-0859-y

15368076

Elimova

Shiozaki

Wadhwa

Sudo

Chen

Estrella

Blum

Badgwell

Das

Song

Ajani

Medical management of gastric cancer: A 2014 update

World J Gastroenterol2013637136472014

10.3748/wjg.v20.i38.13637

25320502

Wei

Costa

Shen

Sanchez

Qian

Sun

Zou

Gimenez-Capitan

Yue

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer

Br J Cancer110266226682014

10.1038/bjc.2014.231

24809779

Pan

Qiu

Zhou

Molecular mechanisms for tumour resistance to chemotherapy

Clin Exp Pharmacol Physiol437237372016

10.1111/1440-1681.12581

27097837

Cree

Charlton

Molecular chess? Hallmarks of anti-cancer drug resistance

BMC cancer17102017

10.1186/s12885-016-2999-1

28056859

Chang

Wooten

Tsimelzon

Hilsenbeck

Gutierrez

Elledge

Mohsin

Osborne

Chamness

Allred

O'Connell

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Lancet3623623692003

10.1016/S0140-6736(03)14023-8

12907009

Kang

Kwon

Chung

Kim

Taxanes in the rreatment of advanced gastric cancer

Molecules21E6512016

10.3390/molecules21050651

27196887

Costa

Halmos

Kumar

Schumer

Huberman

Boggon

Tenen

Kobayashi

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

PLoS Med4166916802007

10.1371/journal.pmed.0040315

17973572

Gong

Somwar

Politi

Balak

Chmielecki

Jiang

Pao

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

PLoS Med4e2942007

10.1371/journal.pmed.0040294

17927446

Kuroda

Puthalakath

Cragg

Kelly

Bouillet

Huang

Kimura

Ottmann

Druker

Villunger

Bim and Bad mediate imatinib-induced killing of Bcr/Abl⁺ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

Proc Natl Acad Sci USA10314907149122006

10.1073/pnas.0606176103

16997913

Wildey

Howe

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

J Biol Chem2818138232006

10.1074/jbc.M505546200

16282323

Brown

Banerji

Maximising the potential of AKT inhibitors as anti-cancer treatments

Pharmacol TherDecember22016(Epub ahead of print)

10.1016/j.pharmthera.2016.12.001

27919797

Sun

Tian

Wang

Yang

The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis

Med Oncol307042013

10.1007/s12032-013-0704-7

23990352

Carbajo-Pescador

Mauriz

García-Palomo

González-Gallego

FoxO proteins: Regulation and molecular targets in liver cancer

Curr Med Chem21123112462014

10.2174/0929867321666131228205703

24372208

de Mattos

S Fernández

Villalonga

Clardy

Lam

FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells

Mol Cancer Ther7323732462008

10.1158/1535-7163.MCT-08-0398

18852127

Vogiatzi

De Falco

Claudio

Giordano

How does the human RUNX3 gene induce apoptosis in gastric cancer? Latest data, reflections and reactions

Cancer Biol Ther53713742006

10.4161/cbt.5.4.2748

16627973

Piñon

Labi

Egle

Villunger

Bim and Bmf in tissue homeostasis and malignant disease

Oncogene27(Suppl 1)S41S522008

10.1038/onc.2009.42

19641506

Sunters

de Mattos

S Fernández

Stahl

Brosens

Zoumpoulidou

Saunders

Coffer

Medema

Coombes

Lam

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines

J Biol Chem27849795498052003

10.1074/jbc.M309523200

14527951

Wei

Kang

The multifaceted role of MTDH/AEG-1 in cancer progression

Clin Cancer Res15561556202009

10.1158/1078-0432.CCR-09-0049

19723648

Wilson

Brosens

Schwenen

Lam

FOXO and FOXM1 in cancer: The FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy

Curr Drug Targets12125612662011

10.2174/138945011796150244

21443467

Lemke

Biology of the TAM receptors

Cold Spring Harb Perspect Biol5a0090762013

10.1101/cshperspect.a009076

24186067

Jia

Ren

Liu

Gong

Wang

Zhang

Zhao

Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma

IUBMB Life665075182014

10.1002/iub.1285

24984960

Hasanbasic

Cuerquis

Varnum

Blostein

Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells

Am J Physiol Heart Circ Physiol287H1207H12132004

10.1152/ajpheart.00020.2004

15130893

Goruppi

Ruaro

Varnum

Schneider

Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras

Oncogene18422442361999

10.1038/sj.onc.1202788

10435635

Holland

Powell

Franci

Chan

Friera

Atchison

McLaughlin

Swift

Pali

Yam

Multiple roles for the receptor tyrosine kinase axl in tumor formation

Cancer Res65929493032005

10.1158/0008-5472.CAN-05-0993

16230391

Tjwa

Bellido-Martin

Lin

Lutgens

Plaisance

Bono

Delesque-Touchard

Hervé

Moura

Billiau

Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes

Blood111409641052008

10.1182/blood-2007-05-089565

18156494

Chong

Yang

Wei

Blanco

Reiss

Haffty

Kang

MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer

Cancer Cell159202009

10.1016/j.ccr.2008.11.013

19111877

Wang

Cai

Wang

Zhao

Song

Meng

Ning

Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III–IV serous ovarian carcinoma

Histopathology609539632012

10.1111/j.1365-2559.2012.04182.x

22372608

Hong

Peng

Chen

Sehdev

Belkhiri

ABL regulation by AXL promotes cisplatin resistance in esophageal cancer

Cancer Res733313402013

10.1158/0008-5472.CAN-12-3151

23117882

Figure 1.

Kaplan-Meier estimates of overall survival in all patients according to the messenger RNA levels of B-cell lymphoma 2 interacting mediator of cell death. BIM, B-cell lymphoma 2 interacting mediator of cell death; OS, overall survival.

Figure 2.

Kaplan-Meier estimates of overall survival in all patients according to the messenger RNA levels of astrocyte elevated gene-1. AEG-1, astrocyte elevated gene-1; OS, overall survival.

Figure 3.

Kaplan-Meier estimates of overall survival in all patients according to the messenger RNA levels of AXL. OS, overall survival.

Figure 4.

Kaplan-Meier estimates of overall survival in patients receiving docetaxel-based second-line chemotherapy according to the messenger RNA levels of B-cell lymphoma 2 interacting mediator of cell death. BIM, B-cell lymphoma 2 interacting mediator of cell death; OS, overall survival.

Table I.

Patient characteristics.

Characteristics	All patients N (%)	Patients receiving only first-line chemotherapy N (%)	Patients receiving second-line chemotherapy N (%)	P-value
Total, N (%)	131 (100.0)	75 (100.0)	56 (100.0)
Age, years				0.330
<60	63 (48.1)	32 (42.7)	31 (55.4)
≥60	68 (51.9)	43 (57.3)	25 (44.6)
Gender				0.410
Female	31 (23.7)	20 (26.7)	11 (19.6)
Male	100 (76.3)	55 (73.3)	45 (80.4)
Tumor site				0.270
Distal stomach	50 (38.2)	25 (33.3)	25 (44.6)
Proximal stomach	38 (29.0)	24 (32.0)	14 (25.0)
Whole stomach	42 (32.1)	25 (33.3)	17 (30.4)
Unknown	1 (0.8)	1 (1.4)	0 (0.0)
Stage				0.550
III	79 (60.3)	44 (58.7)	35 (62.5)
IV	52 (39.7)	31 (41.3)	21 (37.5)
ECOG PS				0.390
0–1	119 (90.8)	66 (88.0)	53 (94.6)
2	12 (9.2)	9 (12.0)	3 (5.4)
Histological grade				0.070
G2	35 (26.7)	20 (26.7)	15 (26.8)
G2-3	35 (26.7)	17 (22.7)	18 (32.1)
G3	59 (45.0)	37 (49.3)	22 (39.3)
Uknown	2 (1.6)	1 (1.3)	1 (1.3)

ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Table II.

Sequences of primers and probes.

Gene	Primers	Probes
β-actin	F 5′-TGAGCGCGGCTACAGCTT-3′	6-FAM 5′-ACCACCACGGCCGAGCGG-3′ TAMRA
	R 5′-TCCTTAATGTCACGCACGATTT-3′
AEG-1	F 5′-GGGGAAGGAGTTGGAGTGAC-3′	6-FAM 5′-AATATTTTCTGGCATTGGGTCTA-3′ MGB
	R 5′-GTAGACTGAGAAACTGGCTCAGCAG-3′
AXL^b	F 5′-CAGCGCAGCCTGCATGT-3′	6-FAM 5′-CAGGGCTGAACAAGAC-3′ MGB
	R 5′-GCGTTATGGGCTTCGCAG-3′
BIM	Assay-on-Demand BIM (ID#Hs00708019_s1)^a

Assay-on-Demand BIM (ID#Hs00708019_s1; catalogue no. 4331182; Life Technologies; Thermo Fisher Scientific, Inc.).

AXL is a receptor tyrosine kinase that belongs to the Tyro3, AXL and Mer family. AEG-1, astrocyte elevated gene-1; BIM, B-cell lymphoma 2 interacting mediator of cell death; 6-FAM, 6-carboxyfluorescein; TAMRA, tetramethylrhodamine; MGB, minor groove binder.

Table III.

Association between gene expression and clinicopathological characteristics in all patients.

Characteristics	Patients, N (%)	Median overall survival, months (95% confidence interval)	P-value
Age, years			0.300
<60	63 (48.1)	12.5 (7.8–17.1)
≥60	68 (51.9)	10.9 (8.7–13.0)
Gender			0.630
Female	31 (23.7)	11.7 (7.2–16.2)
Male	100 (76.3)	11.3 (8.9–13.6)
Tumor site			0.110
Distal stomach	50 (38.2)	11.3 (8.9–13.6)
Proximal stomach	38 (29.1)	15.9 (11.0–20.9)
Whole stomach	42 (32.1)	9.9 (9.0–10.7)
Unknown	1 (0.8)	–
Stage			0.001
III	79 (60.3)	12.9 (9.1–16.7)
IV	52 (39.7)	9.6 (7.5–11.6)
ECOG PS			<0.001
0–1	119 (90.8)	12.5 (9.9–15.1)
2	12 (9.2)	6.3 (0.7–11.9)
Histological grade			0.070
G2	35 (26.7)	12.6 (2.2–23.0)
G2-3	35 (26.7)	12.4 (7.2–17.6)
G3	59 (45.0)	10.6 (9.1–11.1)
Unknown	2 (1.6)	–
BIM mRNA levels			0.170
Low	34 (25.9)	11.6 (8.4–14.7)
Intermediate	35 (26.7)	18.2 (3.9–32.5)
High	35 (26.7)	10.6 (8.1–13.0)
Not detected	27 (20.7)	–
AEG-1 mRNA levels			0.360
Low	42 (32.1)	10.9 (8.9–12.8)
Intermediate	40 (30.5)	10.0 (6.9–13.1)
High	42 (32.1)	12.5 (9.4 −15.7)
Not detected	7 (5.3)	–
AXL mRNA levels^a			0.250
Low	41 (31.3)	12.8 (10.9 −14.7)
Intermediate	43 (32.8)	12.4 (7.9–17.0)
High	43 (32.8)	10.7 (8.9–12.5)
Not detected	4 (3.1)	–
Second-line chemotherapy			0.060
Yes	56 (42.7)	15.0 (8.3–11.9)
No	75 (57.3)	10.1 (13.0–17.0)

AXL is a receptor tyrosine kinase that belongs to the Tyro3, AXL and Mer family. ECOG, Eastern Cooperative Oncology Group; PS, performance status; BIM, B-cell lymphoma 2 interacting mediator of cell death; AEG-1, astrocyte elevated gene-1; mRNA, messenger RNA.

Table IV.

Median OS and HRs for risk of mortality in all patients.

	Only first-line FOLFOX chemotherapy				First-line FOLFOX plus second-line docetaxel-based chemotherapy

Variable	Median OS (95% CI)	P-value	Risk of mortality, HR (95% CI)	P-value	Median OS (95% CI)	P-value	Risk of mortality, HR (95% CI)	P-value
Stage		0.180				<0.001
III	10.9 (8.6–13.1)		0.66 (0.34–1.26)	0.210	20.3 (12.5–28.1)		0.37 (0.17–0.82)	0.010
IV	8.9 (6.3–11.5)		1.00 (reference)		9.7 (7.8–11.6)		1.00 (reference)
ECOG PS		0.001				0.110
0–1	10.6 (8.4–12.7)		0.34 (0.14–0.82)	0.020	15.1 (11.8–18.4)		0.17 (0.04–0.65)	0.010
2	6.3 (0.0–15.3)		1.00 (reference)		8.1 (0.6–15.7)		1.00 (reference)
Histological grade		0.240				0.140
G2	12.1 (10.3–13.9)		0.65 (0.30–1.41)	0.270	20.2 (1.9–38.5)		0.90 (0.33–2.45)	0.840
G2-3	7.5 (6.4–8.7)		1.57 (0.73–3.40)	0.250	17.3 (12.1–22.4)		0.60 (0.26–1.33)	0.200
G3	10.0 (9.0–11.0)		1.00 (reference)		11.3 (6.3–16.3)		1.00 (reference)
BIM levels		0.180				0.008
Low	12.1 (9.0–15.2)		0.79 (0.42–1.47)	0.450	9.6 (8.9–10.3)		2.61 (1.21–5.62)	0.010
Intermediate and high	9.6 (7.3–11.9)		1.00 (reference)		18.2 (12.8–23.6)		1.00 (reference)

ECOG, Eastern Cooperative Oncology Group; PS, performance status; BIM, B-cell lymphoma 2 interacting mediator of cell death; OS, overall survival; HR, hazard ratio; CI, confidence interval; FOLFOX, folinic acid and 5-fluorouracil.